What are the real-world patterns of initiation, titration, and persistence for guideline-directed medical therapies in heart failure?
Real-world evidence highlights significant clinical inertia in heart failure management, with delayed initiation and poor uptitration of novel therapies, though dapagliflozin shows better persistence.
Initiation of novel GDMTs is delayed compared with other GDMTs. Few patients received target doses of GDMTs requiring uptitration. Persistence was higher for dapagliflozin than other GDMTs.
Savarese et al. (2022) studied this question.